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Abstract 
 
Noninvasive early detection of breast cancer through the use of biomarkers is urgently needed 
since the risk of recurrence, morbidity, and mortality is closely related to disease stage at the 
time of primary surgery. A crucial issue in this approach is the availability of relevant markers 
and corresponding monoclonal antibodies suitable for the development of effective 
immunodiagnostic modalities. The identification of such markers from human pathological 
lesions and the isolation of specific antibodies using conventional approaches remain major 
challenges. Camelids produce functional antibodies devoid of light chains of which the single 
N-terminal domain of the heavy chain is fully capable of antigen binding. When produced as 
an independent domain, these so-called single-domain antibody fragments (sdAbs) or 
nanobodies have several advantages for biotechnological applications owing to their unique 
properties of size (13 kDa), stability, solubility, and expression yield.  
In this work, we have generated phage display libraries from animal immunized with breast 
cancer biopsies. These libraries were used to isolate sdAbs against known and relevant 
antigens such as HER2, or several cancer-specific sdAbs against unknown targets. We 
describe the identification of one these targets, cytokeratin 19, using affinity purification in 
combination with mass spectrometry. Some of these sdAbs were used in several 
straightforward diagnostic applications such as immunohistochemistry analysis of tumor 
samples, multiplexed cytometric bead array analysis of crude samples, or an immune 
enrichment procedure of rare cells. Here, we demonstrate that phage display-based selection 
of single-domain antibodies is an efficient and high-throughput compatible approach to 
generate binders with excellent characteristics for the fast development of diagnostic and 
prognostic modalities. 
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Introduction 
 
Breast cancer is the most common cancer among women in Western countries. In 
France, 41,000 new cases are diagnosed each year and 25% of these women are below the age 
of 50. Breast cancer has a heterogeneous behavior and the frequency of metastasis in regional 
lymph nodules depends on tumor types
1
. Overall survival in breast cancer patients has been 
improved by the development of screening and treatment methods. While the 1980s saw a 
sharp rise in the number of new cases of breast cancer, that number now appears to have 
stabilized
1
. The drop in the death rate from breast cancer is probably due to the fact that more 
women are having mammograms. When detected early, the chances for successful treatment 
of breast cancer are considerably improved. 
However, the early diagnosis of breast cancer and an appropriate follow-up after 
surgical treatment are still major issues for the treatment of breast cancer. Mammographic 
imaging is the most effective approach to the diagnosis of breast cancer in women older than 
50 years of age. Although new improvements are being made in the resolution of these 
imaging techniques, tumors smaller than 5 mm usually go undiagnosed
2
, and high-grade 
tumors can evolve very significantly during the interval between two check-up of regular 
mammography imaging, i.e. one to two years. For these reasons, new approaches are urgently 
needed to improve the early diagnosis of breast cancer and the overall and disease-free 
survival rates of patients.  
Many studies have demonstrated significant variations of the expression level of 
several proteins during cancer development. These changes may cause measurable alterations 
of cancer cells and secretion of marker proteins into body fluids such as serum. Such tumor 
markers for breast cancer used in the clinic include cancer antigen 15-3 (CA 15-3), 
carcinoembyonic antigen (CEA)
3
, and HER2
4
. Antibody-based techniques such as 
immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA) are widely used 
for diagnostic purposes of several antigens such as HER2, CEA, CA15-3 or hormonal 
receptors. For example, HER2 is a 185 kDa protein composed of three domains: a 
cytoplasmic domain, a transmembrane domain, and an extracellular domain (ECD). The ECD 
of HER2 can be cleaved from the surface of breast cancer cells by matrix metalloproteases 
and released into the serum. Increased levels of ECD (≥ 15 ng/mL) can be detected in 
approximately 15% to 30% of unselected presurgical breast cancer samples and in up to 45% 
of patients with metastatic breast cancer
5
. Measuring HER-2 is important for selecting optimal 
therapy and predicting prognosis in breast cancer patients. Current methods for evaluating 
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HER-2 include the detection of shed antigen in the serum by enzyme-linked immunosorbent 
assay (ELISA)
6
, or the analysis of protein overexpression by IHC. IHC is now frequently used 
in the evaluation of many epithelial proliferations. Improved antigen retrieval techniques and 
a better understanding of biology have contributed to the broader utility of IHC for solving 
everyday diagnostic problems in breast pathology
7
. 
 In addition, new emerging antibody based approaches are now in development for 
breast cancer diagnosis. For example, microarray multiplex protein measurement of 
biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to 
become a large growth segment of the immunodiagnostic industry. Protein microarrays are 
among the novel class of rapidly emerging proteomic technologies that might lead to efficient 
and specific diagnosis
8
. Microbead protein arrays use surface-coupled capture molecules and 
flow cytometry to simultaneously quantify several antigens. Multiplexing is achieved by 
either using different sized microbeads or color coding that is readable by a laser-induced 
fluorescent detection system
9
. This latter approach is suitable for the analysis of up to a 
hundred different bead-bound antibodies and/or proteins in a complex mixture. These assays 
can be directly compared to ELISA method
10
, but they require smaller volumes of sample 
material, and can be multiplexed. Thus bead array represents the method of choice for low 
density antibody array for clinical use such as diagnosis or prognosis
11, 12
. This technique has 
the potential to generate non invasive and high throughput assay for screening and follow-up 
of large populations of women.  
 Another emerging and interesting diagnostic approach is the detection of circulating 
tumor cells (CTC) as an indicator of metastatic disease. Their detection is expected to provide 
a powerful tool for cancer prognosis, diagnosis of minimal residual disease, assessment of 
tumor sensitivity to anticancer drugs, and personalization of anticancer therapy
13
.  CTC 
detection in blood samples may also be used to diagnose cancer and monitor a patient's 
response to therapy. Since CTCs are rare, comprising about one tumor cell among billions of 
normal blood cells in advanced cancer patients
14
, their detection and enumeration is a difficult 
task. Breast cancer circulating tumor cells are typically extracted from circulation through 
positive selection using epithelial cell-adhesion molecule (EpCAM), or HER2 as markers, 
leading to currently unknown biases when cells are undergoing epithelial-to-mesenchymal 
transition
14
. To increase the specificity of this assay, one solution could be to use a large panel 
of antibodies targeting several membrane tumor antigens.  
All this approaches are dependent on the availability of a variety of specific 
monoclonal antibodies (mAb). Unfortunately, it is not always easy to identify non-cross 
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reactive mAbs against a large variety of markers. Moreover, their high production cost and 
their stability after immobilization are limiting factors for the development of some diagnostic 
assay
15, 16
. The availability of large libraries of recombinant antibody fragments such as single 
chain Fv (scFv) or Fab is especially suited for these  approaches but the stability and 
production yield of these fragments remain a limiting factor
17
. In 1993, Hamers-Casterman et 
al
18
 discovered that sera of camels, dromedaries and llamas contain a unique type of 
antibodies devoid of light chains. Camelids produce functional antibodies devoid of light 
chains (HCAbs).  Single domain antibodies (sdAbs), corresponding to the variable domain of 
these antibodies have several advantages for biotechnological applications
19, 20
 thanks to their 
unique properties including a small size (13 kDa), a high stability even in the absence of 
disulfide bond formation
21
, a high solubility, and high expression yields
22
. Phage display 
technology has been extensively used to isolate tumor specific antibodies able to bind their 
cognate antigens in the cellular context
23-29
. It can be used to isolate binders against tumor 
specific markers
30-35
.  
In this study, we have used phage display to isolate several relevant anti tumor markers sdAbs 
from immunized libraries. The straightforward use of these sdAbs for diagnostic approaches 
are also presented, including conventional assays such as ELISA or IHC, but also more 
innovative approaches such as multiplexed analysis of a complex sample by cytometric bead 
array (CBA) and the enrichment of rare cells in a complex sample by magnetic beads 
followed by flow cytometry characterization.  
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Results 
 
Selection of phage antibodies 
 
Phage display was used to isolate antibodies against breast cancer specific targets. Various 
selection strategies were performed to obtain sdAbs against known and unknown targets.  
 
Selection of anti-HER2 sdAbs 
 
Although breast cancer is a very heterogeneous disease, 20–30% of tumors overexpress the 
human epidermal growth factor receptor 2 (HER2)
36
. SdAbs against this target are thus highly 
relevant for a diagnosis approach. To isolate such sdAbs, a llama was immunized with HER2-
expressing ovarian cancer cell line SKOv3 and a sdAb library was built and used to perform 
biopannings. The first round of selection was performed on purified recombinant HER2 
ectodomain fused to a human Fc portion (HER2-Fc) followed by a second round on HER2-
positive SKBr3 cell line. After selection, 188 clones were screening and 92 clones were found 
positive by ELISA on HER2 positive cells (data not shown). Twenty clones were analyzed by 
sequencing, and all of them corresponded to a unique clone named C7b. The fine specificity 
of this clone was confirmed by ELISA (Fig. 1A). SdAb C7b specifically bound to HER2-Fc 
fusion but not to an irrelevant Fc fusion, demonstrating its specificity for the HER2 
ectodomain. Next, we used a flow cytometric based assay
37
 to determine the affinity of this 
sdAb on cells naturally overexpressing HER2, and compared to the affinity of a dimeric 
version of this sdAb (obtained by Fc fusion and called C7b-Fc) and to the FDA-approved 
anti-HER2 monoclonal antibody (Herceptin/trastuzumab) (Fig. 1B). The precise KD values 
were determined using the non-linear curve fitting program Prism (GraphPad)  The affinity of 
the monovalent sdAb was 7 nM, 11-fold less than the bivalent herceptin affinity determined in 
parallel (600 pM). However, the measured affinity of C7b-Fc, a bivalent format of sdAb C7b 
directly comparable to Herceptin (bivalent IgG), was 200 pM, i.e. threefold higher than the 
one of Herceptin (Fig. 1B). To confirm the affinity of sdAb C7b using an independent 
approach, a competitive ELISA using recombinant HER2-Fc antigen in solution was set up. 
The calculated KD of 5.3 nM (Fig. 1C) was in close agreement with the flow cytometry data. 
Finally, we performed a competition analysis by flow cytometric assay between sdAb C7b 
and Herceptin (Fig. 1D). A large excess of Herceptin could not compete out sdAb C7b, 
demonstrating that these two molecules do not share their epitope. 
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Selection of breast cancer-specific sdAbs of unknown specificity 
   
To select binders against unknown breast cancer markers, llamas were immunized with breast 
cancer biopsy lysates. Phage libraries were built and panned using various approaches. 
Several selections were performed on different samples including a mixture of 9 breast cancer 
cell lines (BT474, SKBr3, HCC1954, MCF7, MDA-MB-231, T47D, HCC1806, BRCA-Mz-
01, HCC1937) and a mixture of 11 biopsy lysates (5801, 5772e, 5766, 5586, 5572i, 5592, 
5011, 5712, 5713, 5033, 5627). After two rounds of panning, a primary screening was 
performed by phage-sdAb ELISA on maxisorp-adsorbed lysates corresponding to each 
selection. Positive clones were selected to perform a secondary screening step against 11 
breast cancer biopsy lysates, a mixture of 9 breast cancer cell line lysates, one healthy breast 
cell line (HME1) as control of cancer specificity, and one patient PBMC (peripheral blood 
mononuclear cells) lysate as control of epithelial cell specificity. A final set of 20 unique 
clones were selected based on the diversity of their phage ELISA profile on breast cancer cell 
lines and biopsies and for their specificity of cancer sample. Fig 2A shows representative 
examples of this various patterns, including a clone binding to antigen differentially expressed 
in biopsies and cell lines, but negative on PBMC lysate (KE9), a clone showing a specificity 
restricted to breast cancer lysates and yielding no signal on biopsy lysates (KE36), or clones 
able to bind biopsy lysates but not cell line lysates (KE21 and KE15).  
 
To establish the possibility to use sdAbs in diagnostic assay without the need of conventional 
mAbs, we tested the possibility to step up a sandwich ELISA using a couple of sdAbs 
targeting different epitopes of the same unknown cancer marker. To determine a relevant 
sdAb couple, series of sandwich ELISA were performed with all binders previously selected 
on various lysates. A couple of sdAbs leading to robust signals (KE23 for capture and KE32 
for detection) was chosen as a proof of concept (data not show). This couple of sdAbs was 
used to determine the presence of their antigen in a mix of various breast cancer cell line and 
biopsy lysates by sandwich sdAb ELISA (Fig. 2B). The results suggest than the targeted 
antigen is differentially expressed in breast cancers. No signal was obtained using a lysate of 
healthy breast cell line (HME1) or human PBMC lysates, suggesting a specificity of these 
sdAbs for epithelial cancers.  
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For most application, the identification of antigens recognized by these binders is of interest 
and permits the identification of monoclonal antibodies to be used in a sandwich approach for 
sensitive and quantitative determination of the antigen concentration in various disease 
samples. As a proof of concept, an approach was designed to elucidate the nature of the 
antigen recognized by sdAb KE9. This sdAb was produced in the cytoplasm of E. coli in 
fusion with the avitag to allow an efficient and directed in vivo enzymatic biotinylation by 
BirA
38
. The purified in vivo biotinylated sdAb was incubated with magnetic streptavidin 
beads before being incubated with one cell line lysate leading to strong signal by phage 
ELISA (T47D). A negative control was performed by using this lysate with an irrelevant 
sdAb anti-Nef 
39
. A SDS-PAGE analysis of the immunoprecipitation revealed several strong 
specific bands in the 50 kDa range (Fig. 3A). Mass spectrometry analysis of these bands 
identified the precipitated proteins as cytokeratin 19 (KRT19). The nature of KE9 antigen was 
confirmed by sandwich ELISA using KE9 as capture antibody, an anti-KRT19 mAb as 
detecting reagent and purified commercial KRT19 as antigen (Fig. 3B).  
  
Immunohistochemistry assays using single domain antibodies 
 
IHC is a common procedure performed that has acquired an increasingly prominent role in the 
diagnosis of breast pathology. To evaluate the efficiency of the selected single domain 
antibodies in IHC, we tested their reactivity on frozen embedded ductal breast cancer tissues 
(unrelated to biopsies used for immunization). As shown in Fig. 4, four sdAbs yielded intense 
stainings. Interestingly, various patterns could be obtained. SdAbs KE9, KE23, KE32 stained 
the cytoplasm of epithelial tumor cells whereas sdAb KE21 yielded a strong signal restricted 
to the nucleus of tumor cells. No staining was obtained in the absence of sdAb or using an 
irrelevant sdAb. These results demonstrate that these sdAbs can be efficiently used to detect 
their antigen within this setting, independently of the cellular localization of their antigen. 
 
Multiplexed analysis using single domain antibodies immobilized on fluorescent beads  
 
This straightforward selection approach by phage display opens the possibility to rapidly 
select a variety of binders against various cancer samples and use the selected binders as 
binding unit to establish highly sensitive and quantitative diagnostic approaches. Therefore, 
we aimed at using the previously characterized binders to elaborate a multiplexed diagnostic 
assay for complex but precious samples such as biopsy lysates or patient serum.   
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As a proof of concept, we decided to use previously isolated sdAbs against tumor markers 
HER2 and CEA
25
, together with the anti-KRT19 sdAb and the couple of sdAbs KE23/32 to 
build up a cytometric bead array assay. This approach uses the broad dynamic range of 
fluorescence detection offered by flow cytometry and antibody-coated beads to efficiently 
capture analytes. Each type of bead in the array is coded with a unique fluorescence intensity, 
and is functionalized with a different sdAb, so that beads can be mixed and run 
simultaneously in a single tube. Four types of commercially available fluorescent beads were 
coated with streptavidin to immobilize in vivo biotinylated sdAbs on their surface in an 
orientated fashion
38
. For this proof of concept, a complex sample was elaborated by mixing a 
patient serum containing a previously determined concentration of CEA, a purified 
recombinant HER2-Fc fusion, and the breast cancer biopsy lysate 5712 containing KRT19 
and the unknown target. To evaluate the sensitivity of this approach, the precise concentration 
of KRT19 contained in this lysate was first established by traditional sandwich ELISA by 
comparison with a standard curve obtained with the purified antigen (data not show). All four 
antigens were simultaneously detected using the corresponding mAb for known targets or by 
phage-sdAb (KE32) for the unknown target. As seen in Fig. 5A, all antigens could be 
simultaneously detected with high sensitivity using a small amount (50 µL) of complex 
sample. 
  
Magnetic enrichment of rare cells using single domain antibodies 
 
Streptavidin microbeads (Miltenyi Biotech) compatible with MACSQuant magnetic columns 
were used to evaluate the potential of biotinylated sdAbs as capture reagent for the 
enrichment of rare cells. As a proof of concept, anti-HER2 sdAb C7b was used to enrich 
breast cancer cells (SKBr3) from a large excess of human PBMC. A SKBr3:PBMC ratio of 
3x10
3
 : 6x10
6
 was chosen to mimic the proportion of CTC in blood. The enrichment was 
monitored by following the percentage of HER2 positive cells using Herceptin. This simple 
procedure led to 276-fold enrichment of tumor cells compared to the initial ratio (Fig. 5B). 
Impressively, more than 97% of HER2 positive cells could be retrieved despite the 2 000-fold 
initial excess of PBMC. 
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Discussion 
 
In this paper, we describe the selection of anti-tumor marker sdAbs and their 
straightforward use in several applications. Using the same library generated by immunization 
of llama with breast cancer biopsies, we selected sdAbs against known and relevant antigens 
such as HER2, or various sdAbs against unknown targets. Finally, some of these sdAbs were 
used to elaborate a sensitive and specific multiplexed assay on CBA to analyze a complex 
breast cancer representative sample. Other applications such as classical 
immunohistochemistry and an efficient and specific immune-enrichment of rare cells are also 
shown.   
Surprisingly, a direct coating of cell lysates used for selections on maxisorp 96 well 
plates could be used to characterize the binding specificity of selected clones against a wide 
range of cell line and biopsy lysates. The high complexity of these lysates and the possible 
conformational changes of antigens due to the adsorption process might have prevented the 
generation of high signal for the monoclonal phage ELISA screening assay. We found that 
most selected phage clones could properly bind their antigens in these conditions. Bound 
phage were detected using an HRP-labeled  monoclonal antibody directed toward p8, present 
at around 2800 copies per phage particle and allowing a considerable signal amplification. As 
such, phage ELISA on immobilized lysates represents a sensitive, robust, inexpensive and 
HT-compatible reverse phase array assay that can be exploited to test hundreds of binders 
against dozens of cell lysates. This approach could be used to generate antigenic profiles of 
various cancer related samples including cell line, biopsies or fluids such as serum samples. 
We have shown the possibility to identify the antigen recognized by the selected 
phage-sdAbs. In a previous work, we had demonstrated the feasibility to produce active 
sdAbs in the cytoplasm of E. coli, fused to the avitag, a 15 aminoacid sequence which is 
biotinylated on a single lysine by E. coli enzyme BirA. This approach allows the efficient and 
inexpensive production of biotinylated sdAbs which can be directly immobilized on 
streptavidin coated surfaces such as plates or beads, in a near covalent and oriented fashion
38
. 
Here we have used this approach to immobilize sdAbs on magnetic streptavidin beads to 
immunoprecipitate the corresponding antigen. This approach was significantly more efficient 
than other ones, including the use of in vitro biotinylated sdAbs with streptavidin beads, his6-
sdAbs with cobalt chelating beads, or direct covalent coupling of sdAb to epoxy beads (data 
not show). As proof of concept, the target of phage-sdAb KE9 was identified as cytokeratin 
19 (KRT19). KRT19 is a relevant antigen for breast cancer analysis and is already used for 
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immunohistochemistry analysis
40
, as tumor marker for serum analysis
41, 42
 and for circulating 
tumor cells detection
43
. This result suggests that the proposed approach is capable of leading 
to the discovery of new relevant cancer related targets and biomarkers.  
The in vivo biotinylation approach was also used to generate a sensitive multiplexed 
cytometry bead array. This assay can be directly compared to ELISA method
10
, but requires 
smaller volumes of sample material, and can be multiplexed. Thus bead array represents the 
method of choice for low density antibody array for clinical use such as diagnosis or 
prognosis
11, 12
. SdAbs have a tendency to bind cryptic epitopes normally inaccessible to 
conventional antibodies
25
. The anti-HER2 sdAb or the anti-KRT19 sdAb selected in this work 
seem to follow the same trend since they do not compete with trastuzumab or a commercial 
anti-KRT19 mAb, respectively. This characteristic facilitates the design of sandwich assays 
once the antigen is identified. Because we used in vivo biotinylation leading to the addition of 
a single biotin at the C-terminus of sdAbs, we could use fluorescently coded streptavidin 
beads that were coupled to a single sdAb before being mixed and incubated with the sample. 
This approach bypasses the need to covalently bind each chosen sdAb to a batch of 
fluorescent bead, and allows the HT-compatible generation of multiplexed bead arrays.  
 A necessary step in metastasis is the dissemination of malignant cells into the 
bloodstream, where cancer cells travel throughout the body as CTC in search of an 
opportunity to seed a secondary tumor. CTC detection represents a valuable diagnostic tool 
and can be used as liquid biopsy for prognostic and predictive purposes. There has been a 
push toward developing technologies to reliably detect CTC using a variety of molecular and 
immunocytochemical techniques. One of the numerous problems of CTC purification is the 
heterogeneous nature of CTC, and the difficulty to define appropriate specific antigens for 
their detection. The availability of several sdAbs targeting new anti-tumor makers might be 
helpful. Here, as proof of this concept, we describe a sensitive and powerful enrichment 
procedure of rare tumor cells using an anti-HER2 sdAb. Importantly, this system is highly 
flexible and only relies in the availability of relevant anti-tumor sdAbs. The use of two 
different sdAbs for targeting two markers for the capture and the detection is an easy way to 
enhance the specificity of this assay. The proposed approach to generate anti-tumor sdAbs 
being fully compatible with high throughput approaches; it becomes feasible to test various 
sdAb combinations to optimize this CTC assay.   
Thus, the combination of phage display and single domain antibody technology 
appears as an attractive approach to rapidly generate a variety of binder whose characteristics 
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are especially well adapted to the generation of inexpensive but powerful diagnostic tools for 
breast cancer diagnosis. 
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Materials and methods  
 
Proteins 
 
sdAb CEA17 was previously described 
25
. 
Herceptin is a kind gift of Daniel Olive (CRCM, Marseille, France) 
Plasmid pET-14b was used to produce in vivo enzymatically biotinylated sdAbs. All sdAbs 
produced in this vector carry a C-terminal his6-tag, preceded by the Avitag
TM
 
(GLNDIFEAQKIEWHE). For generation of plasmids coding for sdAb-avitag
TM
-his6, see 
38
.  
To subclone sdAbs isolated by selection in pHEN1-PhoA-6HisGS plasmid 
44
 in plasmids 
coding for sdAb-avitag
TM
-his6
38
, sdAb was first amplified from pHEN1-sdAb-myc-his6 using 
primers pHENpETAvirev (CGTTCAGACCTGCGGCCGCTGAGGAGACAGTGACCTGG) and pHENpETAvifor 
(CTTTAAGAAGGAGATATACCATGGCCGAGGTGCAGCTGGTG). Vector pET-sdAbaNef –avitag-his6 was 
digested with NcoI and NotI and purified. Cloning by recombination was performed with In-
Fusion™ Advantage PCR Cloning Kits (clontech) as recommended by the manufacturer. All 
constructs were verified by nucleotide sequencing. 
To subclone sdAbs isolated by selection (in pHEN1 plasmid) in plasmids coding for sdAb-Fc 
(Fc from human IgG1), sdAbs were first amplified from pHEN1-sdAb-myc-his6 using 
primers 5HLsecVHH (GGTTGCGTAGCTGAAACCGGTGAGGTGCAGCTGGTG) and 3VHHendH 
(CGGTGGGCATGTGTGAGTTTTGTCTGAGGAGACGGTGACCTG). Vector pHLsec-sdAb-Fc was digested with 
AgeI and BstEII and purified. Cloning by recombination was performed using In-Fusion™ 
Advantage PCR Cloning Kits (clontech) as recommended by the manufacturer. All constructs 
were verified by nucleotide sequencing. 
 
Serum sample, cells lines, biopsies 
 
Patient sera were kindly provided by Pr. J.H.M. Cohen, (Université de Reims Champagne-
Ardenne, Reims). Concentration of soluble CEA in patient sera varied between 150 and 750 
ng/ml while CEA negative sera have a concentration of CEA lower than 5 ng/ml.  
 
MC38 are a kind gift of A. Pelegrin (INSERM U896, IRCM, Montpellier, France), MCF7, 
SKBr3, SKOv3 and T47D are a kind gift of Daniel Olive. MDA-MB-231 and HCC1937 are a 
kind gift of Marie Alix Poul (Laboratoire de Biologie et Pharmacologie Appliquée, Centre 
National de la Recherche Scientifique, UMR8113, Ecole Normale Supérieure de Cachan, 
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France). BrCa-Mz-01, HCC1806, HCC1954 and BT474 are a kind gift of Jean Imbert 
(INSERM, U928, TAGC, Marseille, France). Cells lines MC38, SKOv3, MDA-MB-231, 
MCF7, T47D, HCC1937 were cultured in DMEM complemented with 10% (v/v) fetal calf 
serum. Cells lines SKBr3, HCC1954, BrCaMz01, BT474 and HCC1806 were cultured in 
RPMI complemented with 10% (v/v) fetal calf serum. HME1 cell line was purchased from 
ATCC and grown as recommended by the manufacturer. All cell lines were incubated at 37°C 
in a humidified atmosphere and with 5% CO2. PBMC were isolated by ficoll gradient from 
the blood of healthy donors.  
Informed consent was obtained from each patient prior to biopsy. Breast cancer biopsies 
references: (5801, 5772e, 5766, 5586, 5572i, 5592, 5011, 5712, 5713, 5033, 5627). 
Biopsies or cells were lysed with a potter in lysis buffer : 150 mM NaCl, 1% Triton X-100, 50 
mM Tris HCl pH8 with protease inhibitor cocktail (Complete, Roche). The lysate was 
centrifuged 10 min at 13000 g at 4°C. Supernatant was the final cell lysate. Total protein 
concentration (average between 2-5 mg/ml) was determined spectrophotometrically using a 
protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). 
 
Production, purification and in vitro biotinylation of sdAbs 
 
Production and purification procedures of in vivo biotinylated sdAbs was performed as 
described 
38
.  
In vitro biotinylation of protein was performed using Ez-link micro NHS-PEO4- biotinylation 
kit (Perbio science) following the recommendation of the manufacturer.  
 
Llama immunization and library construction 
 
Three young adult llamas (Lama glama) were immunized subcutaneously at days 1, 30, 60, 90 
and 120 with breast cancer biopsy lysate (4701, 4952) or with healthy breast biopsy (one 
biopsy lysate per animal). One llama was immunized with 50 million of SKOv3 cells which 
strongly express HER2. VHH library construction was performed as described 
25, 45
. Briefly, 
genes coding for VHH were amplified by RT-PCR from the total RNA of peripheral blood 
mononuclear cells isolated by ficoll gradient, and cloned into phagemid pHEN1. 
 
Selection of phage–sdAbs 
 
Page 15 of 29 Molecular BioSystems
15 
 
Phage-sdAb library was produced as described in 
25
 using KM13 helper phage.  
Different strategies of panning were performed. Phage selection were performed using 
antigen-coated magnetic epoxy beads (Dynabeads, invitrogen, following recommendations of 
the manufacturer), using 96-well maxisorp plate (Nunc) coated with antigen overnight at 4°C, 
or using 2x10
6 
intact cells.. Beads, plate or cells were washed three times in PBS (using a 
magnetic particle concentrator for magnetic beads and centrifugation step for cells). Phage-
sdAb library (1 ml) and beads, cells or plate were saturated in milk PBS 2%. For selection 
including a depletion step, phage-sdAb libraries were incubated with depletion support with 
rotation during 2 h at room temperature or at 4°C for cells. Phage-sdAb libraries (depleted or 
not) were recovered and incubated with beads or plate with rotation during 2 h at room 
temperature or at 4°C for cells. Next, beads, cells or plate were washed ten times with 1 ml of 
PBS 0,1% Tween (without tween for cells) and twice with PBS. Phage fixed on beads, cells or 
plates were eluted with tryspin solution (Sigma) at 1 mg/ml during 30 min at room 
temperature with rotation. Eluted phages were treated as described in 
25
.  
 
ELISA assays 
 
ELISA on epoxy beads 
HER2-Fc or human Fc (R & D systems)  were immobilized on magnetic epoxy beads 
(Dynabeads, invitrogen) during 48 h at 4°C following recommendation of the manufacturer. 
For ELISA, 2 µl of beads/well were used. Beads were blocked with 5% milk-PBS (MPBS) 
for two hours at RT. Beads were washed and incubated for 1h at RT with 50 µl of 2% MPBS 
containing in vivo biotinylated sdAbs CEA17 or C7b at 10 µg/ml or HRP-conjugated anti-Fc 
mAb at 1 µg/ml. After three washes with PBS, beads with sdAbs were incubated with HRP-
conjugated streptavidin (Jackson) (1 µg/ml) in 2% MPBS for one hour at RT. After three 
washes in PBS, bound antibodies were detected using ABTS. Coloration was followed at 405 
nm. 
Competitive ELISA on epoxy beads for affinity determination 
A fixed concentration of in vivo biotinylated sdAb C7b (2 µg/mL) was added to serial 
dilutions of soluble HER2-Fc antigen (fivefold dilutions starting from 1.25 µM). After 1 h of 
incubation at RT, the remaining free fraction of biotinylated sdAb C7b was measured by 
incubating the mixture with 2 µl of HER2-Fc immobilized beads per well (prepared as above) 
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for 30 min at RT. After washing, bound sdAbs were detected as above. Dissociation constant 
was calculated using the non-linear curve fitting program Prism (GraphPad). 
 
Phage-sdAb ELISA with lysate for screening and profiling 
Monoclonal phage-sdAbs were produced as described in 
25
. Phage-containing supernatants 
were tested for binding by ELISA. 
Fifty µl/well of biopsy (5734, 5772ext, 5712, 5586, 5766, 5801, 5572int, 5592, 5627, 5011, 
5033, 5713) or cell (BT474, SKBr3, HCC1954, MCF7, MDA-MB-231, T47D, HCC1806, 
BRCA-Mz-01, HCC1937, HME1, MC38, PBMC) lysates (200 µg/ml of total proteins) were 
coated overnight at 4°C on maxisorp 96-well plate (Nunc). After three washes with PBS, 
plates were blocked with 5% MPBS for two hours at RT. Plates were incubated for 1 h at RT 
with 25 µl/well of phage-containing supernatants mixed to  25 µl/well of 4% MPBS. After 
three washes with PBS Tween 0.1% and three washes in PBS, plates were incubated with 
HRP-conjugated anti-M13 mAb (Pharmacia) diluted 1/5000 for 1 h at RT. After three washes 
with PBS Tween 0.1% and three washes in PBS, bound secondary antibodies were detected 
using ABTS. Coloration was followed at 405 nm. 
 
ELISA using a couple of sdAbs 
Streptavidin plates (Thermo scientific) were blocked with 5% milk-PBS (MPBS) for two 
hours at RT. Fifty µl/well of in vivo biotinylated sdAb at 10 µg/ml in 2% MPBS were 
incubated overnight at 4°C. Wells were washed and incubated for 1h at RT with 50 µl of 2% 
MPBS containing cell (BT474, SKBr3, HCC1954, MCF7, MDA-MB-231, T47D, HCC1806, 
BRCA-Mz-01, HCC1937, HME1, MC38, PBMC) or biopsy (5734, 5772ext, 5712, 5586, 
5766, 5801, 5572int, 5592, 5627, 5011, 5033, 5713) lysates at 100 µg/ml of total proteins. 
After three washes with PBS tween 0.1% and three washes in PBS, plates were incubated 1 h 
at RT with 25 µl/well of phage-containing supernatants mixed to  25 µl/well of 4% MPBS. 
Following three washes with PBS tween 0.1% and three washes in PBS plates were incubated 
with HRP-conjugated anti-M13 mAb diluted 1/5000 for 1 h at RT. After three washes with 
PBS Tween 0.1% and three washes in PBS, bound secondary antibodies were detected using 
ABTS. Coloration was followed at 405 nm. 
 
Flow cytometry analysis 
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Experiments were performed on ice with rocking in 1% BSA PBS. Typically, 2x10
5
 cells 
resuspended in 50 µl were distributed in 96-well microtiter plate, and incubated for 1 h with 
various concentrations of in vitro biotinylated antibodies. After washing, binders were 
detected with PE conjugated streptavidin (1:10) (Beckman Coulter). Fluorescence was 
measured using a MACSQuant (Miltenyi) and results were analyzed with the MACSQuant 
software. Negative (secondary antibody only) controls were carried out.  
 
Immunoprecipitation  
 
Cell lysates were depleted by incubation with magnetic streptavidin beads (Dynabeads, 
Invitrogen) for 2 h at RT. In the same time, in vivo biotinylated sdAbs were incubated with 
magnetic streptavidin beads during 1 h at RT (4 µg of sdAbs for 100 µl of beads for one 
immnoprecipitation). Beads were washed 3 times with PBS and incubated with depleted cell 
lysates during 2 h at RT under agitation. Beads with immune complexes were washed 5 times 
in lysis buffer and heated to 95°C for 5 min in 10µl of non-reducing protein loading buffer.  
 
In-gel digestion and MALDI-TOF MS.  
 
Protein spots excised from Coomassie blue (Imperial Protein stain, Pierce) stained gels were 
subjected to in-gel digestion with trypsin (Sequencing grade modified porcine trypsine; 
Promega, Madison, WI, USA) according to a modified protocol from Shevchenko et al. 
46
. 
Tryptic peptides were then extracted from the gel, pooled and dried in a Speedvac evaporator. 
Mass analyses were performed on a MALDI-TOF-TOF Bruker Ultraflex spectrometer 
(Bruker Daltonics, Wissembourg, France) controlled by the Flexcontrol 3.0 package (Build 
173.1). A list of contaminant ions was constituted from a blank sample (blank piece of gel 
treated and analysed exactly as a true sample) and substracted from sample peaklists before 
database search. The peptide mass lists were used to identify the protein using MASCOT 
software 2.2 (Matrix Science) available on site.  
 
Immunochemistry assay 
 
in vivo biotinylated nanobodies were tested in immunostaining on 5 µm sections of frozen-
embedded cancer tissus. Endogenous peroxidase activity was blocked by incubation with 3% 
H2O2. Slides were incubated for 1 h with 10 µg/ml of in vivo biotinylated nanobodies at RT. 
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Detection was performed by incubations at RT for 30 min with streptavidin peroxidase. 
Visualization was performed by DAB revelation (Dako) peroxidase reaction with 
haematoxylin as counterstain. 
 
CBA assay 
 
Three types of CBA Functional Bead system (BD Biosciences) were used for the assay.  
The Functional Bead Conjugation Buffer Set was used for conjugation of streptavidin to 
beads following the recommendation of the manufacturer.  
For multiplexed assay, 1.5x10
5
 beads of each type were used per assay. The whole procedure 
was performed in the dark. Beads were coated with sdAbs individually and all types of beads 
were mixed for the rest of the procedure. Beads were blocked with 3% BSA PBS for 2 h at 
RT. Beads were incubated with in vivo biotinylated sdAb (C7b, CEA17, KE9) at 10 µg/ml in 
1% BSA PBS for 1 h at RT. After two washes with PBS, all bead types were mixed and 
incubated for 1 h at RT with serial dilutions of sample containing patient serum with CEA, 
recombinant HER2-Fc (R & D systems) and a lysate of biopsy 5712. After two washes with 
PBS, beads were incubated for 1 h at RT with 2 µg/ml of anti-HER2 mAb (Santa-Cruz, sc-
74241), anti-CK19 mAb (Santa-Cruz, sc-53258) and anti-CEA mAb 35A7 (kind gift of A. 
Pelegrin, Montpellier). After two washes with PBS, beads were incubated for 1 h at RT with 
PE-conjugated goat anti-mouse mAb (Santa cruz) diluted 1/200. Fluorescence was measured 
using a MACSQuant (Miltenyi) and results were analyzed with the MACSQuant software. 
Negative controls (secondary antibody only) were carried out.  
 
Rare cells enrichment assay 
 
The enrichment procedure was performed using Streptavidin Microbeads (Miltenyi Biotech) 
following the recommendation of the manufacturer. Capture antibody was in vitro 
biotinylated sdAb C7b at 10 µg/ml. Detection antibody was Herceptin labeled with Alexa660 
at 10 µg/ml. Labeling was performed using Alexa Fluor® 660 Protein Labeling Kit 
(Molecular Probes, Invitrogen) following the recommendation of the manufacturer. We used a 
ratio of 3 000 SKBr3 cells mixed with 6 000 000 of human PBMC. 
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Figure legends 
 
Figure 1: sdAb C7b specificity and affinity. A) Epoxy beads were coated with HER2-Fc or 
Fc antigen, and incubated with anti-HER2 (C7b) or anti-CEA (CEA17) in vivo biotinylated 
sdAbs. Bound sdAbs were detected with HRP-conjugated streptavidin. HRP-conjugated anti–
Fc mAb were used as positive control of the presence of Fc fragments on beads. B) SKBr3 
cells were incubated with serial dilutions of in vitro biotinylated sdAb C7b (●), Herceptin (■) 
or C7b-Fc (▲). Captured antibodies were detected by PE-conjugated streptavidin. Cells were 
analyzed by flow cytometry assay on MACSQuant. Error bars represent the standard 
deviation of MFI (mean fluorescence intensity) of experiments performed in triplicates. KD 
values were determining using non-linear fitting program Prism (GraphPad) C) 2 µg/mL of in 
vitro biotinylated sdAb C7b was incubated with various concentrations of soluble HER2-Fc 
antigen. The free fraction of biotinylated sdAb was measured by incubation with bead 
coupled to HER2-Fc followed by washing and detection using streptavidin-HRP. Error bars 
represent the standard deviation of experiments performed in triplicates. D) SKBr3 cells were 
incubated with serial dilutions of Herceptin (1 to 0.000001 µM). In vitro biotinylated 
Herceptin at 0.001 µM (●) or sdAb C7b at 0.01 µM (■) were added. Captured antibodies were 
detected by PE-conjugated streptavidin. Cells were analyzed by flow cytometry assay on 
MACSQuant. Error bars represent the standard deviation of experiments performed in 
triplicates. 
 
Figure 2: Phage-ELISA characterization of isolated sdAbs. A) Reverse phase ELISA. 
Maxisorp plate were coated with soluble protein lysate of biopsies (11 different biopsies), a 
mixture of breast cancer cell lines, named BC cell lines in the figure, and containing cell line 
lysates BT474, SKBr3, HCC1954, MCF7, MDA-MB-231, T47D, HCC1806, BRCA-Mz-01, 
HCC1937, human PBMC and healthy breast cell line HME1. Phage-sdAbs were added. 
Bound phage were detected with HRP-conjugated anti-M13 mAb. B) Sandwich sdAb ELISA. 
In vivo biotinylated sdAb KE23 was immobilized on streptavidin plates at 10 µg/ml. Lysates 
of biopsies (same as in A), a mixture of breast cancer cell lines (BC cell lines, same as in A), 
human PBMC and healthy breast cell line HME1 were added. After washing, KE32 phage-
sdAb was added and bound phage were detected by HRP-conjugated anti-M13 mAb. 
Figure 3: Targets identification. A) In vivo biotinylated KE9 sdAb or control sdAb (Cont.) 
were immobilized on streptavidin beads and used to perform immunoprecipitation using 
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T47D cell line lysates. Immunoprecipitated proteins were analyzed under non-reducing 
conditions by SDS-PAGE. The low molecular weight bands correspond to streptavidin and 
immobilized sdAbs. B) Streptavidin plate were coated with in vivo biotinylated sdAb KE9. 
KRT19 antigen was added. After washing, anti-KRT19 mouse antibody was added and bound 
mAb were detected by HRP-conjugated anti-mouse antibody.  
Figure 4: Immunohistochemistry assay. Frozen embedded ductal breast cancer tissue slides, 
corresponding to different samples, were incubated with in vivo biotinylated sdAbs. Bound 
sdAbs were detected by HRP-conjugated streptavidin. Original magnification, x20. 
 
Figure 5: Breast cancer diagnosis assay with sdAbs. A) Multiplexed analysis of four breast 
cancer specific targets in a complex sample using a CBA assay. CBA beads were coated with 
streptavidin and incubated with in vivo biotinylated sdAb C7b, CEA17, KE9 or KE23. All 
beads were mixed and incubated with serial dilutions of serum containing CEA (starting 
concentration: 500 ng/ml), HER2-Fc antigen (starting concentration: 10 µg/ml), and  biopsy 
5712 lysate (starting concentrations: 100 µg/ml of total protein and 7 µg/ml of KRT19). 
Beads were incubated with phage-sdAb KE32 , anti-CEA, anti-HER2 and anti-KRT19 mouse 
antibody.  Anti-M13 mAb was added, followed by PE-conjugated goat-anti-mouse mAb. 
Beads were analyzed by flow cytometry assay on MACSQuant. Error bars represent the 
standard deviation of MFI (mean fluorescence intensity) of experiments performed in 
triplicates. B) Enrichment of rare cells. Enrichment of initial mixture of SKBr3 cells (3 000) 
in human PBMC (6 000 000) yielding an initial ratio of 0.05% of cancer cells. Cancer cells 
were enriched using in vitro biotinylated anti-HER2 sdAb C7b loaded on streptavidin 
microbeads, and detected with Alexa660 labeled Herceptin. Enrichment procedure was 
performed on the MACSQuant cytometer and analyzed by flow cytometry on the same 
device. 
Page 24 of 29Molecular BioSystems
Figure 1
A
HER2-Fc Fc
0
1
2
3
4
5
sdAb C7b
sdAb CEA17
anti Fc
O
D
B
10-8 10-7 10-6 10-5 10-4 10-3 10-2 10-1 100 101
0
20
40
60
80
100
sdAd C7b
Herceptin
C7b-Fc
Antibodies (µM)
M
F
I
Herceptin biot.
C
10-6 10-4 10-2 100
0
20
40
60
80
100 sdAb C7b biot.
Herceptin (µM)
M
F
I
10-3 10-2 10-1 100 101 102 103
0.0
0.5
1.0
1.5
2.0
HER2-Fc (nM)
O
D
D
Page 25 of 29 Molecular BioSystems
KE15
1.5
2.0
KE21
1.5
2.0
KE36
0.0
0.5
1.0
1.5
2.0
O
D
KE9
0.0
0.5
1.0
1.5
2.0
O
D
Figure 2 
A
0.0
0.5
1.0
O
D
0.0
0.5
1.0
O
D
B KE23/32
0.0
0.5
1.0
1.5
2.0
O
D
Page 26 of 29Molecular BioSystems
Figure 3
B
0.0
0.5
1.0
1.5
2.0
O
D
A
KE9 Cont.MW
100
75
50
37
25
20
5 0 
KRT19 (µg/ml)
15
Page 27 of 29 Molecular BioSystems
KE9 KE21
KE23 KE32
Figure 4
Without sdAb
Irrelevant sdAb
Page 28 of 29Molecular BioSystems
Figure 5
HER2
10-4 10-3 10-2 10-1 100 101 102
0
200
400
600
800
HER2-Fc (µg/ml)
M
F
I
CEA
10 -6 10-5 10 -4 10 -3 10-2 10 -1 100
0
100
200
300
400
CEA (µg/ml)
M
F
I
KRT19
60
KE23/KE32
200
A
10-5 10 -4 10 -3 10 -2 10 -1 100 101
0
20
40
KRT19 in biopsy (µg/ml)
M
F
I
10 -1 100 101 102 103
0
50
100
150
Total protein of biopsy lysate (µg/ml)
M
F
I
B
Capture 
sdAb
Total cells
Total cells
(% recovery)
HER2+ 
cells
HER2+ cells
(% recovery)
HER2+ 
cells (% 
final)
Enrichment
C7b 18650 0.31 2938 97.9 16.56 276
Page 29 of 29 Molecular BioSystems
